II. Class
- Rifamycin
- Inhibits Bacterial RNA Polymerase
III. Mechanism
- Long-acting Rifampin derivative
IV. Indications
V. Contraindications
- Children under age 2 years
- Latent Tuberculosis with suspected resistance to Isoniazid or Rifampin
- HIV patients on Antiretrovirals (due to lower drug levels and risk of resistance)
- Unknown safety in pregnancy
VI. Dosing
-
Tuberculosis
- Part of multi-drug regimen; high risk of drug resistance Tb if used alone
- Rifapentine 600 mg orally twice weekly for 2 months then once weekly for 4 months
- Latent Tuberculosis
VII. Adverse Effects
- See Rifampin
- Hyperuricemia
- Body secretion discoloration (orange to brown)
- Discolors urine and Contact Lenses
- Hepatotoxicity (uncommon)
- Thrombocytopenia
- Neutropenia (rare)
VIII. Drug Interactions
- See Rifampin
- Metabolized by Cytochrome P-450 3A3/4
IX. Monitoring
- Baseline Liver Function Tests and clinical evaluations
Images: Related links to external sites (from Bing)
Related Studies
| Definition (NCI) | A long-acting, cyclopentyl-substituted derivative of rifamycin used to treat mycobacterium infections. |
| Concepts | Antibiotic (T195) , Organic Chemical (T109) |
| MSH | C018421 |
| SnomedCT | 108686006, 410831004 |
| English | 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)rifamycin, 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)rifamycin SV, rifapentine, rifapentine (medication), rifapentine [Chemical/Ingredient], Rifapentine (substance), Rifapentine, Rifapentine (product), RIFAPENTINE |
| Spanish | rifapentina (sustancia), rifapentina, rifapentina (producto) |
Ontology: Priftin (C0876758)
| Concepts | Antibiotic (T195) , Organic Chemical (T109) |
| MSH | C018421 |
| English | Priftin, Aventis Behring brand of rifapentine |
